TY - CONF
T1 - Hemodynamic and demographic characteristics of potential patients to undergo balloon pulmonary angioplasty at Pauls Stradiņš Clinical University Hospital
AU - Kalējs, Verners Roberts
AU - Rudzītis, Ainārs
AU - Lejnieks, Aivars
AU - Šablinskis, Matīss
AU - Šablinskis, Kristaps
AU - Kigitoviča, Dana
AU - Kauliņš, Ričards
AU - Skride, Andris
AU - Vītola, Barbara
PY - 2021/3/24
Y1 - 2021/3/24
N2 - In the recent RACE trial, balloon pulmonary angioplasty (BPA) was found to be more effective than treatment with riociguat in non-operable CTEPH patients (Jais et al., 2018). The aim of this study is to summarize baseline characteristics of CTEPH patients who are selected to potentially undergo BPA at Pauls Stradiņš Clinical University Hospital (PSCUH). This is a registry study of Latvian PH registry summarizing baseline characteristics of symptomatic (WHO-FC II-IV), non-operable CTEPH patients, with baseline assessment from May-December 2020 and were deemed eligible by multidisciplinary CTEPH team to undergo BPA within the framework of project “Implementation of BPA and evaluation of its effectiveness in treatment of CTEPH at PSCUH” approved by Latvian Council of Science.Most recent right heart catheterization (mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index (CI)) and echocardiography (Tricuspid Annular Plane Systolic Excursion (TAPSE), left ventricular ejection fraction (LVEF)) data, six-minute walking distance (6MWD) and B-type natriuretic peptide (BNP) levels are presented as mean ±SD, where applicable. 15 patients were included in this study, 8 (53%) were female. Mean age was 65 ±6 years. Most patients were WHO-Functional Class III (WHO-FC II/III/IV; 4/10/1). All patients were receiving vasodilator therapy, with 5 patients (33%) (95% CI: 15-59%) being on dual-combination therapy.
Mean mPAP, and PVR showed progressed PH (49 ±8 mmHg and 9.1 ±2.2 Wood) with impaired CI (2.09 ±0.24 L/min/m2), albeit mostly preserved Left heart (LVEF 55 ±7%), and right heart (TAPSE 18 ±2 mm) function seen on echocardiography. The burden of PH was reflected in elevated BNP levels (386.2 ±189.7 pg/ml). Mean 6MWD of 267 ±59 m showed severe functional impairment. According to ESC/ERS (2015) guidelines, these patients had several high mortality risk factors. Creation of the first BPA center in the Baltic States would offer additional treatment options for this patient cohort.
AB - In the recent RACE trial, balloon pulmonary angioplasty (BPA) was found to be more effective than treatment with riociguat in non-operable CTEPH patients (Jais et al., 2018). The aim of this study is to summarize baseline characteristics of CTEPH patients who are selected to potentially undergo BPA at Pauls Stradiņš Clinical University Hospital (PSCUH). This is a registry study of Latvian PH registry summarizing baseline characteristics of symptomatic (WHO-FC II-IV), non-operable CTEPH patients, with baseline assessment from May-December 2020 and were deemed eligible by multidisciplinary CTEPH team to undergo BPA within the framework of project “Implementation of BPA and evaluation of its effectiveness in treatment of CTEPH at PSCUH” approved by Latvian Council of Science.Most recent right heart catheterization (mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index (CI)) and echocardiography (Tricuspid Annular Plane Systolic Excursion (TAPSE), left ventricular ejection fraction (LVEF)) data, six-minute walking distance (6MWD) and B-type natriuretic peptide (BNP) levels are presented as mean ±SD, where applicable. 15 patients were included in this study, 8 (53%) were female. Mean age was 65 ±6 years. Most patients were WHO-Functional Class III (WHO-FC II/III/IV; 4/10/1). All patients were receiving vasodilator therapy, with 5 patients (33%) (95% CI: 15-59%) being on dual-combination therapy.
Mean mPAP, and PVR showed progressed PH (49 ±8 mmHg and 9.1 ±2.2 Wood) with impaired CI (2.09 ±0.24 L/min/m2), albeit mostly preserved Left heart (LVEF 55 ±7%), and right heart (TAPSE 18 ±2 mm) function seen on echocardiography. The burden of PH was reflected in elevated BNP levels (386.2 ±189.7 pg/ml). Mean 6MWD of 267 ±59 m showed severe functional impairment. According to ESC/ERS (2015) guidelines, these patients had several high mortality risk factors. Creation of the first BPA center in the Baltic States would offer additional treatment options for this patient cohort.
M3 - Abstract
SP - 135
T2 - RSU Research week 2021: Knowledge for Use in Practice
Y2 - 24 March 2021 through 26 March 2021
ER -